Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen)

Azuma,Haruhito; Inamoto,Teruo; Takahara,Kiyoshi; Nomi,Hayahito; Uehara,Hiroshi; Komura,Kazumasa; Minami,Koichiro; Kouno,Junko; Kotake,Yatsugu; Abe,Hirokazu; Takagi,Shizuko; Yamamoto,Kazuhiro; Narumi,Yoshihumi; Kiyama,Satoshi

doi:10.3892/ijo.2013.1923

Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen)

Authors:
- Haruhito Azuma
- Teruo Inamoto
- Kiyoshi Takahara
- Hayahito Nomi
- Hiroshi Uehara
- Kazumasa Komura
- Koichiro Minami
- Junko Kouno
- Yatsugu Kotake
- Hirokazu Abe
- Shizuko Takagi
- Kazuhiro Yamamoto
- Yoshihumi Narumi
- Satoshi Kiyama
View Affiliations

Affiliations: Department of Urology, Osaka Medical College, Takatsuki city, Osaka 569-8686, Japan, Department of Urology, Saiseikai Nakatsu Hospital, Osaka city, Osaka 530-0012, Japan, Department of Urology, Shizuoka Saiseikai Hospital, Shizuoka city, Shizuoka 422-8527, Japan, Department of Urology, Hirakata City Hospital, Hirakata city, Osaka 573-1013, Japan
Published online on: April 26, 2013 https://doi.org/10.3892/ijo.2013.1923
Pages: 79-87

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We have developed a novel form of bladder preservation therapy [OMC (Osaka Medical College)-regimen] involving balloon-occluded-arterial-infusion (BOAI) of an anticancer agent (cisplatin/gemcitabine), used concomitantly with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation. We previously reported that the OMC-regimen elicited a complete response (CR) in >90% of patients with organ confined tumors, while LN(+), T4 tumors and a non-UC histological type were statistically significant risk factors for treatment failure and patient survival. In this study, we investigated the effects of the OMC-regimen in patients with organ confined urothelial cancer tumors and the outcomes were compared to those with total cystectomy. Three hundred and one patients were assigned to receive either the OMC-regimen (n=162) or total cystectomy (n=139). Patients in the OMC-regimen group who failed to achieve CR underwent cystectomy, or secondary BOAI with an increased amount of CDDP or gemcitabine (1600 mg). The OMC-regimen yielded 98.1% of clinical response; CR in 93.8% (152/162) of patients; PR in 4.3% (7/162). More than 96% of the CR patients (146/152) were alive with no evidence of recurrence after a mean follow-up of 166 (range 23-960) weeks. No patients suffered grade III toxicity; all patients successfully completed this therapy. The patient survival was significantly better compared to the cystectomy group; the overall 5-, 10- and 15-year survival rates were 87.3, 79.6 and 59.7%, respectively. Moreover, the 5-, 10- and 15-year bladder intact survival rates, the most important issue for bladder preservation therapy, were 85.7, 78.4 and 58.8%, respectively. In conclusion, the OMC-regimen is a useful bladder-preservation strategy, not only in those for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom palliation would otherwise seem the only option.

View Figures

View References

1.	Schlegel PN and Walsh PC: Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol. 138:1402–1406. 1987.PubMed/NCBI
2.	Pagano F, Bassi P, Galetti TP, et al: Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol. 145:45–50. 1991.
3.	Stenzl A, Cowan NC, De Santis M, et al: Guidelines on bladder cancer: muscle-invasive and metastatic. Eur Assoc Urol. 3:1–59. 2008.
4.	Hong S, Kwak C, Jeon H, Lee E and Lee S: Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy? Urology. 65:697–702. 2005. View Article : Google Scholar : PubMed/NCBI
5.	Leissner J, Koeppen C and Wolf H: Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol. 169:955–960. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Patton S, Hall M and Ozen H: Bladder cancer. Curr Opin Oncol. 14:265–272. 2002. View Article : Google Scholar
7.	Shelley MD, Barber J and Wilt T: Surgery versus radiotherapy for invasive bladder cancer. Cochrane Database Syst Rev. CD002079. 2002.
8.	Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol. 19:666–675. 2001.PubMed/NCBI
9.	Dalbagni G, Genega E, Hashibe M, et al: Cystectomy for bladder cancer: a contemporary series. J Urol. 165:1111–1116. 2001. View Article : Google Scholar : PubMed/NCBI
10.	Frazier H, Robertson J, Dodge R and Paulson D: The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 71:3993–4001. 1993. View Article : Google Scholar : PubMed/NCBI
11.	Tran E, Souhami L, Tanguay S and Rajan R: Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer. Am J Clin Oncol. 32:333–337. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Weizer AZ, Joshi D, Daignault S, et al: Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J Urol. 177:1287–1293. 2007. View Article : Google Scholar : PubMed/NCBI
13.	Hoshi S, Shintaku I, Suzuki K, et al: Bladder preservation by internal iliac arterial infusion chemotherapy and irradiation in T3 bladder carcinoma patients over the age of 70 years. Tohoku J Exp Med. 192:249–258. 2000.
14.	Kaufman DS, Winter KA, Shipley WU, et al: The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 5:471–476. 2000.
15.	Rodel C, Grabenbauer GG, Kuhn R, et al: Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 20:3061–3071. 2002. View Article : Google Scholar : PubMed/NCBI
16.	Shipley WU, Winter KA, Kaufman DS, et al: Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 16:3576–3583. 1998.
17.	Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 14:119–126. 1996.
18.	Hagan MP, Winter KA, Kaufman DS, et al: RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys. 57:665–672. 2003.PubMed/NCBI
19.	Kaufman DS, Winter KA, Shipley WU, et al: Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology. 73:833–837. 2009. View Article : Google Scholar
20.	Greene FL, Page DL and Fleming ID: AJCC Cancer Staging Manual. 6th edition. Springer Verlag; New York, NY: 2002, View Article : Google Scholar
21.	Ficcara V, Dalpiaz O, Alrabi N, Novara G, Galfano A and Artibani W: Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 95:786–790. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 8:1335–1339. 1979. View Article : Google Scholar : PubMed/NCBI
23.	Douple EB and Richmond RC: Radiosensitization of hypoxic tumor cells by cis- and trans-dichlorodiammineplatinum (II). Int J Radiat Oncol Biol Phys. 8:1369–1372. 1979. View Article : Google Scholar : PubMed/NCBI
24.	Abbott DW, Freeman ML and Holt JT: Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst. 90:978–985. 1998. View Article : Google Scholar : PubMed/NCBI
25.	Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA and Repta AJ: Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep. 63:1515–1521. 1979.PubMed/NCBI
26.	Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ and Sternson LA: Clinical kinetics on intact cisplatin and some related species. Clin Pharmacol Ther. 29:658–664. 1981. View Article : Google Scholar : PubMed/NCBI